Jinyun Chen
Novartis
9 Papers
1 Citations
Jinyun Chen is an academic researcher from Novartis. The author has contributed to research in topics: Mutant & Allosteric regulation. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Allosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity
Xiaoling Xie,Daniel Baird,Kimberly E. Bowen,Vladimir Capka,Jinyun Chen,Gregg Chenail,YoungShin Cho,Julia Dooley,Ali Farsidjani,Pascal D. Fortin,Darcy Kohls,Raviraj Kulathila,Fallon Lin,Daniel J. McKay,Lindsey Rodrigues,David Sage,B. Barry Touré,Simon van der Plas,Kirk Wright,Ming Xu,Hong Yin,Julian Levell,Raymond Pagliarini +22 more
TL;DR: Two structurally distinct mutant- and isoform-selective IDH1 inhibitors that inhibit 2-HG production are characterized and crystal structures of oncogenic IDH2 mutant isoforms are reported, providing a deeper understanding of how IDH 1 inhibitors achieve mutant andisoform selectivity.
60
The Novolactone Natural Product Disrupts the Allosteric Regulation of Hsp70
A. Quamrul Hassan,Christina A. Kirby,Wenlai Zhou,Tim Schuhmann,Roman Kityk,D. Randal Kipp,Jason Baird,Jinyun Chen,Yaoyu Chen,Franklin Chung,Dominic Hoepfner,N. Rao Movva,Raymond Pagliarini,Frank Petersen,Christopher Quinn,Douglas Frederick Quinn,Ralph Riedl,Esther K. Schmitt,Anne Schitter,Travis Stams,Christian Studer,Pascal D. Fortin,Matthias P. Mayer,Heather Sadlish +23 more
TL;DR: Biochemical and structural analyses indicate that novolactone disrupts interdomain communication by allosterically inducing a conformational change in the Hsp70 protein to block ATP-induced substrate release and inhibit refolding activities, making it a valuable tool for exploring the requirements of HSp70 chaperones in diverse cellular contexts.
56
Patent
Biomarkers of tumor pharmacodynamic response
Wenlai Zhou,Jinyun Chen,Christine D. Wilson,Yaoyu Chen +3 more
- 14 Mar 2014
TL;DR: In this paper, the authors proposed a selective cancer treatment regime based on assaying for the presence or absence of a mutation in a nucleic acid that encodes MLL1.
1
Patent
Compositions organiques de traitement de maladies associées à hsf1
Jinyun Chen,Kalyani Gampa,Dieter Huesken,Frank Stegmeier,Mark Stump,Chandra Vargeese,Jan Weiler,Wenlai Zhou +7 more
- 30 Aug 2012
TL;DR: In this article, a method for traitement de maladies associees au facteur de choc thermique 1 (HSF1), telles que le cancer, les maladies auto-immunes and les mal diseases virales, is presented.
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Jinyun Chen,Franklin Chung,Guizhi Yang,Minying Pu,Hui Gao,Wei Jiang,Hong Yin,Vladimir Capka,Shailaja Kasibhatla,Bryan Laffitte,Savina Jaeger,Raymond Pagliarini,Yaoyu Chen,Wenlai Zhou +13 more
TL;DR: It is reported that PHDGH is overexpressed in many ER-negative human breast cancer cell lines, indicating that PHGDH is dispensable for the growth and maintenance of tumors in vivo.